These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21782761)

  • 1. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma.
    Shim JH; Lee HC; Won HJ; Shin YM; Kim KM; Lim YS; Suh DJ
    J Hepatol; 2012 Feb; 56(2):406-11. PubMed ID: 21782761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization.
    Kim BK; Kim SU; Kim MJ; Kim KA; Kim DY; Park JY; Ahn SH; Han KH; Chon CY
    Clin Cancer Res; 2013 Mar; 19(6):1503-11. PubMed ID: 23225115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
    Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
    Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
    Kim CJ; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MJ
    Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
    Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma.
    Park KH; Kwon SH; Lee YS; Jeong SW; Jang JY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ
    Clin Mol Hepatol; 2015 Jun; 21(2):158-64. PubMed ID: 26157753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
    Gillmore R; Stuart S; Kirkwood A; Hameeduddin A; Woodward N; Burroughs AK; Meyer T
    J Hepatol; 2011 Dec; 55(6):1309-16. PubMed ID: 21703196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
    Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
    Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization.
    Kim BK; Kim KA; Kim MJ; Park JY; Kim DY; Ahn SH; Han KH; Kim SU; Park MS
    Dig Liver Dis; 2015 Aug; 47(8):682-8. PubMed ID: 25977216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.